OCT 29, 2019 07:00 AM PDT

Optimizing high-content screening tools for physiologically-relevant 3D in vitro models

SPONSORED BY: Molecular Devices
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Study Director, HCS Pharma
    Biography
      Elodie Vandenhaute, PhD in neurobiology, has been working as a study director in HCS Pharma company since 2017. She received her PhD in 2011 in the laboratory of Pr Romeo Cecchelli (Artois University, France), for her work on the development and characterization of in vitro blood-brain barrier models for fundamental research, and their applications in drug discovery. With different post-doctoral positions in Germany and France, she has acquired wide experience of in vitro modelling for the study of brain cell responses in health and disease (brain metastasis, cerebral amyloid angiopathy, Alzheimer's disease, hypoxia).
    • Senior Scientist, HCS Pharma
      Biography
        Zied Souguir, PhD is Senior Scientist at HCS Pharma. He is currently in charge on the development and industrialization of innovative technology for 3D cell culture. He holds a PhD in chemistry and polymer science from the University of Rouen, France (2006). His PhD dissertation focused on the chemical modification of polysaccharides and the study of the chemical and physicochemical properties of biomaterials. He has coauthored more than 30 publications, patents and conference paper in the area of biopolymer and polysaccharide modification. His current research interests focus on the chemical and physicochemical modification of biomaterials for 3D cell culture.
      • North America BioImaging Director, Molecular Devices
        Biography
          Daniel O'Connor is the North America BioImaging Director for Molecular Devices. He currently plays an integral role in driving the technology innovation and expansion of Molecular Device's High Content Imaging portfolio. He earned his B.S. in Neuroscience from the University of Minnesota and has over 20 years of microscopy and imaging experience with an emphasis on 3D High Content Imaging technologies. He travels nationally consulting with researchers to ensure Molecular Devices is meeting our customer's ever-changing 2D and 3D High Content Imaging needs. When not in the lab he enjoys skiing and trying to golf in MINNESOTA for more than three months a year. He currently resides in Minneapolis with his 3 kids.

        Abstract:

        DATE: October 29, 2019

        TIME: 7:00am PDT, 2:00pm GMT, 3:00pm CET

        3D cell culture systems have recently emerged as tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM).  Join us for this webinar with HCS Pharma, a biotechnology start-up company based in France, as we discuss the biological characterization of cells in 3D matrices for liver, brain and adipose tissues, and cancer modeling, using BIOMIMESYS® hydroscaffold technology. We will also discuss high-content screening solutions for examining 3D in vitro models.

        In this webinar, you will learn from Dr. Zied Souguir, inventor of the BIOMIMESYS® hydroscaffold, about the unique differentiation of this technology and its application for high-throughput drug screening.  Dr. Elodie Vandenhaute, a 3D cell culture expert at HCS Pharma, will demonstrate how to handle 3D cell culture systems such as the BIOMIMESYS hydroscaffold on high-content imagers, and how these can be integrated into HCS platforms in high throughput, such as HCS Pharma’s HAPIx platform. Finally, Daniel O’Connor, Drug Discovery Director (Molecular Devices) will discuss new High-Content Screening (HCS) technologies that are enabling researchers to capture more data at greater depths for 3D and thick tissue samples.

        BIOMIMESYS® hydroscaffold technology mimics the native ECM and allows the culture of cells in a physiologically-relevant 3D cell culture system. It is based on hyaluronic acid, a major component of ECM currently under-represented in cell culture systems, and biofunctionalized with other ECM components according to the organ/tissue of interest. This matrix is provided in cell culture plates in a ready-to-use format and is compatible with all common downstream analytical techniques. It can be used to great benefit in early drug discovery as it is adapted to HCS, ADME-Tox profiling, and disease modeling. 
         

        Key learning objectives:

        • Describe the differentiating factors between different 3D cell culture systems 
        • Utilizing a relevant 3D cell culture platform for liver, brain, adipose tissue, and disease modeling (human cells)
        • Optimizing setup of a high-content screening platform for 3D in vitro models

         

        Webinars will be available for unlimited on-demand viewing after live event.

         

        LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


        Show Resources